Table 1

Baseline characteristics of adalimumab-treated patients and adalimumab exposure by therapeutic indication

CharacteristicsRheumatoid arthritisJuvenile idiopathic arthritisAnkylosing spondylitisPsoriatic arthritis*PsoriasisCrohn's diseaseAll patients
N14 10921216848373010360623 458
Mean age, years53.511.243.148.444.737.448.6
Mean disease duration, years9.83.910.914.619.311.111.4
Female, %78.980.227.547.433.259.765.3
Receiving concomitant immunosuppressant agents, %65.964.638.269.32.843.252.5
Receiving concomitant systemic steroids, %64.453.335.526.84.934.648.7
From US sites, %23.147.68.625.337.537.626.4
Exposure, PYs23 942.6604.91985.6997.55061.84138.036 730.5
Median duration of exposure, years0.72.60.40.40.70.50.6
Maximum duration of exposure, years11.86.95.13.55.75.511.8
>2 Years of exposure, N (%)2503 (17.7)109 (51.4)354 (21.0)312 (37.3)1228 (40.8)703 (19.5)5209 (22.2)
>5 Years of exposure, N (%)1646 (11.7)64 (30.2)140 (8.3)086 (2.9)35 (1.0)1971 (8.4)
  • * Psoriatic arthritis was the only indication with no new data from those previously reported.10

  • Based on the following number of patients with available baseline disease duration information: rheumatoid arthritis, 13 739; juvenile idiopathic arthritis, 195; psoriatic arthritis, 819; Crohn's disease, 3238; and all patients, 22 685.

  • PYs, patient-years.